IS 101
Alternative Names: IS-101Latest Information Update: 13 Jan 2023
At a glance
- Originator InvisiShield Technologies
- Class Antivirals
- Mechanism of Action Mucin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 22 Nov 2022 Preclinical trials in COVID-2019 infections in USA (Intranasal), before November 2022
- 22 Nov 2022 InvisiShield Technologies announces intention to submit IND to US FDA for COVID-2019 infections, before November 2022 (InvisiShield Technologie Pipeline, November 2022)
- 22 Nov 2022 InvisiShield Technologies plans a clinical trial trial for COVID-2019 infections, before November 2022 (InvisiShield Technologie Pipeline, November 2022)